Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2019
27 March 2019 - 8:24PM
Business Wire
- New preclinical data to be presented on
- Core inhibitor EDP-514 targeting
HBV
- FXR agonist EDP-305 targeting NASH
- ASK-1 inhibitors EP-026856 and
EP-027315 targeting NASH
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that new preclinical data from Enanta’s wholly-owned
development programs for hepatitis B virus (HBV) and non-alcoholic
steatohepatitis (NASH) have been accepted for presentations at The
International Liver Congress™ (ILC) 2019, April 10-14, in Vienna,
Austria.
New data will include a presentation on development candidate
EDP-514, Enanta’s core inhibitor for HBV that is expected to enter
into a Phase 1 clinical study in the second half of 2019. There
will also be presentations focused on Enanta’s NASH program,
featuring new data on the FXR agonist EDP-305, and including in
vivo data on EP-027315 and EP-026856, two prototype compounds from
Enanta’s ASK-1 (apoptosis signal-regulating kinase 1) inhibitor
project.
The full ILC 2019 scientific program as well as the abstracts
can be found at
https://ilc-congress.eu/programme-highlights/. Further details will be available at the time of
these presentations.
Poster Presentations at The International Liver Congress™
(ILC) 2019:April 11, 2019 - 09:00 - 19:00THU-084: “A
comparative study of anti-Fibrotic therapeutics using aptamer-based
quantitative proteomics in a rat model of non-alcoholic
steatohepatitis cirrhosis”Smitha Krishnan, United States
April 12, 2019 - 09:00 - 17:00FRI-340: “In vivo effects of a
novel inhibitor of apoptosis signal-regulating kinase 1 in mouse
models of liver injury and metabolic disease”Manuel Roqueta-Rivera,
United States
FRI-191: “EDP-514, a novel HBV core inhibitor with potent
antiviral activity both in vitro and
in vivo”Kai Lin, United States
About EnantaEnanta Pharmaceuticals is using its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery and development of small molecule drugs
for the treatment of viral infections and liver diseases. Enanta’s
research and development efforts are currently focused on the
following disease targets: respiratory syncytial virus (RSV),
non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), and hepatitis B virus (HBV).
Enanta’s research and development activities are funded by
royalties from HCV products developed under its collaboration with
AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is
now sold by AbbVie in numerous countries as part of its newest
treatment for chronic hepatitis C virus (HCV) infection. This
leading HCV regimen is sold under the tradenames MAVYRET™ (U.S.)
and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir). Please visit
www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190327005289/en/
Investor ContactCarol
Miceli617-607-0710cmiceli@enanta.com
Media Contact:Kari WatsonMacDougall Biomedical
Communications781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024